Timed Awake Prone and Repositioning for Patients With Covid-19-induced Hypoxic Respiratory Failure.

Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05689216
Collaborator
(none)
286
3
2
13
95.3
7.3

Study Details

Study Description

Brief Summary

Awake prone positioning has been reported to improve oxygenation for patients with COVID-19. Awake timed and repositioning is a novel method to improve patients' compliance and prolong the prone time. This study aims to explore the impact of timed prone and repositioning on the intubation rate and prognosis of COVID-19 patients with hypoxic respiratory failure.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Awake timed prone and repositioning
N/A

Detailed Description

Patients with COVID-19 may develop severe illness characterized by progressive hypoxic respiratory failure, resulting in the need for invasive mechanical ventilation. Reducing the rate of endotracheal intubation in patients with hypoxic respiratory failure can be beneficial to the prognosis, economize iatrical resources and reduce sanitary investment. Some studies have shown that prone positioning can improve oxygenation to some extent in patients receiving invasive mechanical ventilation due to severe ARDS.

Whether awake prone positioning can reduce endotracheal intubation and mortality in COVID-19 patients with hypoxic respiratory failure is still controversial. A meta-analysis found that the awake prone positioning was safe and feasible to reduce the risk of intubation or death. However, the multicenter randomized controlled trial (RCT) conducted by Alhazzani et al pointed out that the awake prone positioning group did not significantly reduce the rate of endotracheal intubation when compared with the standard of care.

Some researchers thought the time of prone positioning is an important factor for the different results. In previous studies, the median duration of prone positioning was only 4.8-5 hours per day but some guidelines recommend the duration should be more than 8 hours. Therefore, increasing patient adherence in the awake prone positioning and extending prone positioning time are of great importance.

Awake timed prone and repositioning is a novel method proposed in recent years, which can improve patients' compliance and prolong the time of treatment. This study intends to ask whether awake timed prone and repositioning could impact the intubation rate and prognosis of unincubated patients with hypoxic respiratory failure induced by COVID-19.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
286 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Efficacy of Timed Awake Prone and Repositioning in Patients With Covid-19-induced Hypoxic Respiratory Failure: a Multi-center, Randomized Controlled Trial.
Anticipated Study Start Date :
Jan 18, 2023
Anticipated Primary Completion Date :
Feb 18, 2024
Anticipated Study Completion Date :
Feb 18, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Awake timed prone and repositioning group

Patients' cumulative prone and repositioning time is encouraged to reach 8-10 hours per day for 4 days following a timed prone and repositioning strategy.

Behavioral: Awake timed prone and repositioning
Patients were instructed to adopt a timed prone and repositioning strategy with 4 sessions for four consecutive days. Session 1, lying on the belly; Session 2, lying on the right side; Session 3, sitting up; Session 4, lying on the left side; then back to session 1 (30 minutes to two hours for each session). The daily duration of timed prone and repositioning is strongly recommended for 8-10 hours.

No Intervention: Standard care group

Patients can change their positions freely according to their own needs. Health providers do not take the initiative to give guidance on prone and repositioning.

Outcome Measures

Primary Outcome Measures

  1. Endotracheal Intubation rate [Day 30]

    The incidence of endotracheal Intubation within 30 days of study enrollment

Secondary Outcome Measures

  1. Mortality [Day 30]

    All-cause death within 30 days of study enrollment

  2. Days of non-invasive ventilation [Day 30]

    Number of days alive and free of mechanical ventilation within 30 days of study enrollment

  3. Days alive and outside the ICU [Day 30]

    Number of days alive and outside the ICU within 30 days of study enrollment

  4. Clinical events [Day 30]

    Clinical events include time to treatment failure( treatment failure defined as intubation or death); time to intubation; time to death; duration of invasive mechanical ventilation in intubated patients surviving to day 30; mortality in invasively mechanically ventilated patients; and physiological response to awake prone positioning, including the ratio of SpO2:FiO2 to respiratory rate, known as the ROX index.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Adults ≥ 18 years of age

  • Awake patients without endotracheal intubation

  • Suspected or confirmed infection of COVID-19

  • Hypoxemia requiring oxygen supplementation ≥ 0.4 FiO2 or ≥ 5L/min via nasal cannula

  • Bilateral or unilateral chest infiltrates on x-ray or HRCT

  • Admitted to the ICU or an acute care unit where hemodynamic and respiratory

  • Willingness to comply with the protocol and provide written informed consent

Exclusion Criteria:
  • Risk of airway obstruction or even asphyxia

  • Need for emergent intubation after admission

  • Respiratory failure caused by cardiogenic pulmonary edema

  • Unable to implement timed prone and repositioning due to any cause

  • Injury or wound on the ventral body surface affecting the prone position

  • Unstable fracture of cervical vertebra and spine

  • Glaucoma or other sharp increases in intraocular pressure

  • Intracranial hypertension caused by traumatic brain injury etc.

  • Significantly high risk of pulmonary embolism

  • Acute hemorrhagic disease

  • Respiratory rate >40 breaths/min, with significant dyspnea

  • Transcutaneous oxygen saturation can not be continuously monitored

  • Hemodynamic instability requiring vasoactive drugs (systolic blood pressure <90 mmHg or mean arterial pressure <65 mmHg despite adequate volume resuscitation)

  • Awareness disorder or inability to accept instructions, communication barrier with the nursing team, inability to use language or pager to call for help

  • Difficulty or limitation in autonomous movement, inability to adjust the position without assistance from others

  • Body mass index > 37 kg/m2

Contacts and Locations

Locations

Site City State Country Postal Code
1 Changxing People's Hospital Changxing Zhejiang China 313199
2 The Second Affiliated Hospital Zhejiang University School of Medicine Hangzhou Zhejiang China 310000
3 Lishui Municipal Central Hospital Lishui Zhejiang China 323020

Sponsors and Collaborators

  • Second Affiliated Hospital, School of Medicine, Zhejiang University

Investigators

  • Study Chair: Min Yan, M.D., Second Affiliated Hospital, School of Medicine, Zhejiang University

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

Responsible Party:
Min Yan, Chief of Department of Anesthesia and Surgery, Second Affiliated Hospital, School of Medicine, Zhejiang University
ClinicalTrials.gov Identifier:
NCT05689216
Other Study ID Numbers:
  • 2023-0027
First Posted:
Jan 19, 2023
Last Update Posted:
Jan 19, 2023
Last Verified:
Jan 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Min Yan, Chief of Department of Anesthesia and Surgery, Second Affiliated Hospital, School of Medicine, Zhejiang University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 19, 2023